

# Journal Pre-proof

COVID-19 and IL-6: Why Vitamin D (probably) helps but tocilizumab might not

Morry Silberstein

PII: S0014-2999(21)00184-9

DOI: <https://doi.org/10.1016/j.ejphar.2021.174031>

Reference: EJP 174031

To appear in: *European Journal of Pharmacology*

Received Date: 31 December 2020

Revised Date: 10 March 2021

Accepted Date: 11 March 2021

Please cite this article as: Silberstein, M., COVID-19 and IL-6: Why Vitamin D (probably) helps but tocilizumab might not, *European Journal of Pharmacology*, <https://doi.org/10.1016/j.ejphar.2021.174031>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Elsevier B.V. All rights reserved.



**COVID-19 and IL-6: Why Vitamin D (probably) helps but tocilizumab might not**

Morry Silberstein

School of Molecular & Life Sciences

Curtin University

Perth WA, Australia

[m.silberstein@curtin.edu.au](mailto:m.silberstein@curtin.edu.au)

The author declares no conflict of interest.

## **COVID-19 and IL-6: Why Vitamin D (probably) helps but tocilizumab might not**

### **Abstract**

Interleukin 6 (IL-6), which is involved in the cytokine storm phenomenon, is a therapeutic target in COVID-19, but monoclonal receptor antibody therapeutic agents such as tocilizumab have demonstrated mixed results. Could Vitamin D, which modulates IL-6, be more effective than currently deployed IL-6 antagonists, including tocilizumab, thereby presenting a useful therapeutic option in COVID-19? A narrative review of published trials examining the effect of Vitamin D administration in COVID-19 patients was conducted, and the theoretical basis for the use of tocilizumab as an IL-6 antagonist was compared with the immunomodulatory effect of Vitamin D on IL-6 production. Four of the six included studies reported a positive effect of Vitamin D on outcomes. While tocilizumab non-selectively blocks both anti-inflammatory and pro-inflammatory actions of IL-6, Vitamin D lowers immune cell IL-6 production, potentially reducing pro-inflammatory effects, but does not specifically target IL-6 receptors, avoiding any deleterious effect on the anti-inflammatory actions of IL-6. Vitamin D may have advantages over tocilizumab as an IL-6 immunomodulator, and, given that it is safe if administered under clinical supervision, there is a strong rationale for its use.

**COVID-19 and IL-6: Why Vitamin D (probably) helps but tocilizumab might not**

**Keywords**

Vitamin D; COVID-19; IL-6; tocilizumab; cytokine storm

Journal Pre-proof

## COVID-19 and IL-6: Why Vitamin D (probably) helps but tocilizumab might not

### 1. Introduction

Despite the pending widespread rollout of a vaccine, the novel human coronavirus pandemic which began in late December 2019 (Hui et al, 2020) continues to present an enormous challenge, with no currently approved therapeutic regimen (Tobaiqy et al, 2020). Based upon early reports that many patients with severe COVID-19 produced large quantities of interleukins (referred to as a cytokine storm (Ross et al, 2020), the IL-6 antagonist tocilizumab was trialled as a therapeutic option, but results, while initially promising (Tleyjeh et al, 2020), have not fully met the original high expectations (Stone et al, 2020). The term cytokine storm generally refers to a number of cytokines, including IL-6 as well as Tumour Necrosis Factor - TNF (England et al, 2021). Indeed, the use of TNF antagonists for COVID-19 has been proposed (Feldmann et al, 2020), but, at time of writing, there are no published results using this strategy (England et al, 2021).

Vitamin D, which has immunomodulatory properties (Sassi et al, 2020), was proposed as a potential therapeutic option in the early part of the pandemic (Silberstein, 2020b), supported in part by reports of Vitamin D deficiency resulting in poorer outcomes (see the review by Benskin, 2020). Yet, despite calls for clinical trials of this vitamin (Silberstein, 2020b), in part based upon its modulation of IL-6, a key interleukin implicated in viral replication (Silberstein, 2020a), only a few have been completed at time of writing. This comes as a surprise, given the widespread promotion and multiple trials of the IL-6 antagonist tocilizumab (Tleyjeh et al, 2020). There is clearly a need for prospective trials of Vitamin D in COVID-19, but if its mechanism of action involves IL-6 modulation (Sadeghi et al, 2006; Subramanian et al, 2017), will it prove any better than tocilizumab, which has delivered mixed results (Stone et al, 2020)? This review seeks to determine whether the IL-6 modulating properties of Vitamin D may be more effective than

currently deployed IL-6 antagonists, including tocilizumab, thereby presenting a useful therapeutic option in COVID-19.

## **2. Methods**

A limited narrative review of recent clinical trials of therapeutic Vitamin D administration for COVID-19 was performed by searching PubMed and Google Scholar for adult human research studies that included key words “vitamin D” and “Covid-19” and/or “SARS-CoV-2” up to 31 December 2020. A total of 6 studies satisfied the inclusion criteria. As there was heterogeneity in the format of how results were published, analysis was limited to whether administration of Vitamin D resulted in a statistically significant reduction in ICU admission, cytokine levels or mortality.

The theoretical basis for the use of IL-6 antagonist tocilizumab in patients with COVID-19 was also examined, and compared in a narrative format, with the purported effect of Vitamin D on IL-6 and COVID – 19 patient outcomes.

## **3. Results**

There was considerable variation in dosing regimen and outcome measures reported (Table 1). One study - which reported no significant effect of acute Vitamin D treatment on mortality - included a third arm in which patients who underwent 12 months prior maintenance supplementation had significant lower mortality compared to controls (Annweiler et al, 2020). The majority of studies used cholecalciferol, with 3 of these 5 demonstrating a significant effect. The other study reported a significant reduction in Intensive Care Unit admissions following calcifediol administration (Castillo et al, 2020). One study reported a significant reducing effect

of cholecalciferol on fibrinogen levels as a nominated inflammatory marker (Rastogi et al, 2020). Another administered a combination of cholecalciferol, magnesium, and vitamin B<sub>12</sub> and reported a significant reduction in ICU admission and/or O<sub>2</sub> requirement (Tan et al, 2020). In summary, although quite diverse, 4 of the 6 studies reported positive outcomes, while a fifth included a third arm with a positive outcome from prior but not acute supplementation.

#### 4. Discussion

Interleukin 6 (IL-6), a cytokine which initiates intracellular signalling (Rose-John, 2012), is produced by a range of cells, including immune, skeletal, vascular smooth muscle and osteoblasts (Jones and Jenkins, 2018). IL-6 is often referred to as having both anti-inflammatory and pro-inflammatory properties, according to the targeted receptors (Rose-John, 2012). Only a limited number of cell types express IL-6 receptors on their surfaces (referred to as membrane bound receptor or IL-6R), including some epithelial cells and hepatocytes (Rose-John, 2012). The binding of IL-6 to receptors on these cells, referred to as classical signalling, has an anti-inflammatory effect (Rose-John, 2012). This contrasts with trans signalling where cells stimulated by, for example, microbial agents (Walev et al, 1996), shed IL-6 receptors, forming a soluble receptor (sIL6-R) which can then bind to any cell in the body (Chalaris et al, 2011). Trans signalling is deemed to be pro-inflammatory, via recruitment of mononuclear cells, inhibition of T-cell apoptosis and T reg cell differentiation (Rose-John, 2012), and undoubtedly play a substantial role in the COVID-19 cytokine storm (Ross et al, 2020).

Tocilizumab is a monoclonal antibody which targets all IL-6 receptors, regardless of whether they are membrane bound or soluble (16). Clearly tocilizumab and similar non-selective IL-6 antagonists do not discriminate and although administered to modulate pro-inflammatory trans signalling via sIL6-R, will equally block anti-inflammatory classical signalling via membrane bound

IL-6R (Tanaka et al, 2012). This might be the explanation for recent mixed results from tocilizumab in COVID-19 patients (Stone et al, 2020).

Contrast this with Vitamin D, which lowers immune cell IL-6 production (Silberstein, 2020a), potentially reducing pro-inflammatory effects, but does not specifically target IL-6 receptors, avoiding any deleterious effect on the anti-inflammatory actions of IL-6. Vitamin D has also been shown to lower TNF levels (Peterson and Heffernan, 2008), representing an additional therapeutic mechanism for countering the COVID-19 cytokine storm. This would appear to work in theory, but what is the evidence of Vitamin D improving COVID-19 outcomes? There is growing evidence that Vitamin D deficiency is associated with greater COVID-19 morbidity and mortality (Brown, 2020), but the evidence for a direct therapeutic effect is still limited. In the results herein described, 4 of the 6 studies reported positive outcomes, while a fifth included a third arm with a positive outcome from prior but not acute supplementation. As noted, the studies were quite diverse in terms of dosing regimens and outcome measures, but do support further investigation. Only one of the trials examined calcifediol, which results in a more rapid increase in serum 25OHD compared to oral cholecalciferol (Quesada-Gomez and Bouillon, 2018), and it, too, described a positive impact on the outcome measure assessed – ICU admission (Castillo et al, 2020).

The addition of L-cysteine as an adjunct to Vitamin D supplementation also merits consideration. This combination reduces oxidative stress more effectively than Vitamin D alone (Jain et al, 2018; Jain et al, 2020) as well as markers of musculoskeletal dyshomeostasis (Parsanathan et al, 2020) and has been proposed as a more effective therapeutic approach than Vitamin D alone (Jain and Parsanathan, 2020).

There is clearly a need for more clinical trials of Vitamin D in COVID-19, including calcifediol, as well as in combination with L-cysteine, but, given that the risk of toxicity is low when

administered under professional supervision, there is a strong theoretical rationale for widespread Vitamin D prescription.

## **5. Conclusions**

Both Vitamin D and tocilizumab may have therapeutic roles in COVID-19 by exerting immunomodulatory effects on IL-6, but the former, by reducing immune cell IL-6 production may have advantages over the latter which can block both anti and pro inflammatory action of IL-6. Given that Vitamin D is safe if administered under clinical supervision and deficiency is associated with worse outcomes, there is a strong rationale for its use as a specific therapeutic measure.

## References

Annweiler G, Corvaisier M, Gautier J, et al. (2020). Vitamin D Supplementation Associated to Better Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Quasi-Experimental Study. *Nutrients*. 12, 3377. doi:10.3390/nu12113377

Benskin LL. (2020). A Basic Review of the Preliminary Evidence That COVID-19 Risk and Severity Is Increased in Vitamin D Deficiency. *Front Public Health* 8, 513. doi:10.3389/fpubh.2020.00513

Brown RA. (2020). Vitamin D Mitigates COVID-19, say 40+ patient studies (listed below) – yet BAME, elderly, care-homers, and obese are still ‘D’ deficient, thus at greater COVID-19 risk – WHY. <https://www.bmj.com/content/371/bmj.m3872/rr-5>

Castillo LM, Costa LME, Barrios JMV, et al. (2020). Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. *J Steroid Biochem Mol Biol*. 203, 105751. doi:10.1016/j.jsbmb.2020.105751

Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J. (2011). The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. *Eur J Cell Biol* 90, 484-494. doi:10.1016/j.ejcb.2010.10.007

England JT, Abdulla A, Biggs CM, et al. (2021). Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. *Blood Rev* 45, 100707. doi:10.1016/j.blre.2020.100707

Feldmann M, Maini RN, Woody JN, et al. (2020). Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. *Lancet* 395, 1407-1409. doi:10.1016/S0140-6736(20)30858-8

Hui DS, I Azhar E, Madani TA, et al. (2020). The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis* 91, 264-266. doi:10.1016/j.ijid.2020.01.009

Jain SK, Parsanathan R. (2020). Can Vitamin D and L-Cysteine co-supplementation reduce 25(OH)-Vitamin D deficiency and the mortality associated with COVID-19 in African Americans?. *J Am Coll Nutr* 39, 694-699. doi:10.1080/07315724.2020.1789518

Jain SK, Parsanathan R, Achari AE, Kanikarla-Marie P, Bocchini JA Jr. (2018). Glutathione stimulates Vitamin D regulatory and glucose-metabolism genes, lowers oxidative stress and inflammation, and increases 25-Hydroxy-Vitamin D levels in blood: A novel approach to treat 25-Hydroxyvitamin D Deficiency. *Antioxid Redox Signal* 29, 1792-1807. doi:10.1089/ars.2017.7462

Jain SK, Parsanathan R, Levine SN, Bocchini JA, Holick MF, Vanchiere JA. (2020). The potential link between inherited G6PD deficiency, oxidative stress, and vitamin D deficiency and the racial inequities in mortality associated with COVID-19. *Free Radic Biol Med* 161:84-91. doi:10.1016/j.freeradbiomed.2020.10.002

Jones SA, Jenkins BJ. (2018). Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. *Nat Rev Immunol* 18, 773-789. doi: 10.1038/s41577-018-0066-7.

Ling SF, Broad E, Murphy R, et al. (2020). High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study. *Nutrients*. 12, 3799. doi:10.3390/nu12123799

Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, et al. (2020). Effect of Vitamin D3 supplementation vs placebo on hospital length of stay in patients with severe Covid-19: A multicenter, double-blind, randomized controlled trial. medRxiv 2020.11.16.20232397; doi: <https://doi.org/10.1101/2020.11.16.20232397>

Parsanathan R, Achari AE, Manna P, Jain SK. (2020). I-Cysteine and Vitamin D co-supplementation alleviates markers of musculoskeletal disorders in Vitamin D-deficient high-fat diet-fed mice. *Nutrients* 12, 3406. doi:10.3390/nu12113406

Peterson CA, Heffernan ME.(2008). Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. *J Inflamm (Lond)* 5, 10. doi:10.1186/1476-9255-5-10

Quesada-Gomez JM, Bouillon R. (2018). Is calcifediol better than cholecalciferol for vitamin D supplementation? *Osteoporos Int* 29, 1697-1711. doi:10.1007/s00198-018-4520-y

Rastogi A, Bhansali A, Khare N, et al (2020). Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). *Postgrad Med J* Published Online First: 12 November 2020. doi: 10.1136/postgradmedj-2020-139065

Rose-John S.(2012). IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. *Int J Biol Sci* 8, 1237-1247. doi:10.7150/ijbs.4989

Ross R, Frydas I, Kritas SK. (2020). Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents* 34, 327-331. doi: 10.23812/CONTI-E

Sadeghi K, Wessner B, Laggner U, et al. (2006). Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. *Eur J Immunol* 36, 361-370. doi:10.1002/eji.200425995

Sassi F, Tamone C, D'Amelio P. (2018). Vitamin D: Nutrient, hormone, and immunomodulator. *Nutrients* 10, 1656. doi:10.3390/nu10111656

Silberstein M. (2020a). Correlation between premorbid IL-6 levels and COVID-19 mortality: Potential role for Vitamin D. *Int Immunopharmacol* 88,106995. DOI:10.1016/j.intimp.2020.106995

Silberstein M. (2020b). Vitamin D: A simpler alternative to tocilizumab for trial in COVID-19? *Med Hypotheses* 140, 109767. doi:10.1016/j.mehy.2020.109767

Stone JH, Frigault MJ, Serling-Boyd NJ, et al. (2020). Efficacy of tocilizumab in patients hospitalized with Covid-19. *N Engl J Med NEJMoa2028836*. doi: 10.1056/NEJMoa2028836. PMID: 33085857; PMCID: PMC7646626.

Subramanian K, Bergman P, Henriques-Normark B. (2017). Vitamin D promotes pneumococcal killing and modulates inflammatory responses in primary human neutrophils. *J Innate Immun* 9, 375-386. doi:10.1159/000455969

Tan CW, Ho LP, Kalimuddin S, Cherng BPZ, Teh YE, Thien SY, et al. (2020). Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B<sub>12</sub> in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). *Nutrition* 79-80, 111017. doi: 10.1016/j.nut.2020.111017.

Tanaka T, Narazaki M, Kishimoto T. (2012). Therapeutic targeting of the interleukin-6 receptor. *Annu Rev Pharmacol Toxicol* 52, 199-219. doi: 10.1146/annurev-pharmtox-010611-134715.

Tleyjeh IM, Kashour Z, Damlaj M, et al. (2020). Efficacy and safety of tocilizumab in COVID-19 patients: A living systematic review and meta-analysis. *Clin Microbiol Infect* S1198-743X(20)30690-X. doi:10.1016/j.cmi.2020.10.036

Tobaiqy M, Qashqary M, Al-Dahery S, et al. (2020). Therapeutic management of patients with COVID-19: a systematic review. *Infection Prevention in Practice* 2:100061. doi:10.1016/j.infpip.2020.100061

Walev I, Vollmer P, Palmer M, Bhakdi S, Rose-John S. (1996). Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. *Proc Natl Acad Sci USA* 93, 7882-7887. doi:10.1073/pnas.93.15.7882

**Table 1**

Reference	Location	Measure	Age (years)	N T/C	Vitamin	Duration	Dose	Outcome
Annweiler, et al	France	Mortality	88 ± 5	16/32	CCC	Single	80,000 IU	P = 0.50
Castillo, et al	Spain	ICU	53 ± 10	50/26	CCD	≥ 7 days	0.532 mg	P < 0.001
Ling, et al.	UK	Mortality	74 ± 9	164/162	CCC	Variable	≤ 40,000 IU/day	P < 0.001
Murai, et al.	Brazil	Mortality	56 ± 15	120/120	CCC	Single	200,000 IU	P = 0.59
Rastogi, et al	India	Fibrinogen	49 ± 6	16/24	CCC	≥ 7 days	60,000 IU/day	P = 0.007
Tan, et al.	Singapore	ICU or O <sub>2</sub>	62 ± 7	17/26	CCC	≤ 14 days	1000 IU/day	P = 0.006

**Legend for Table:**

**Table 1.** Analysis of impact of Vitamin D supplementation on COVID-19 outcome in published controlled trials.

The first column lists first author for each study. The fifth column (N) refers to Treated/Controls. The sixth column refers to Cholecalciferol (CCC) or Calcifediol (CCD). The final column details reported statistical effect of Vitamin D on outcome measure.

**Morry Silberstein**  
**(hereinafter the "Copyright Owner")**  
**JOURNAL PUBLISHING AGREEMENT**

**PLEASE PROVIDE US WITH THE FOLLOWING INFORMATION, REVIEW OUR POLICIES AND THE JOURNAL PUBLISHING AGREEMENT, AND INDICATE YOUR ACCEPTANCE OF THE TERMS**

Article entitled: COVID-19 and IL-6: Why Vitamin D (probably) helps but tocilizumab might not

Corresponding author: Dr Morry Silberstein

To be published in the journal: European Journal of Pharmacology

**YOUR STATUS (PLEASE MARK ALL THAT APPLY)**

**I am the sole author of the manuscript**

Please indicate which of the below applies to you:

- I am a UK, Canadian or Australian Government employee and Crown Copyright is asserted
- I am a US Government employee and the Article is public domain and therefore the 'Assignment of copyright' clause does not apply
- I am a contractor of the US Government under contract number: .....

**None of the above**

**I am one author signing on behalf of all co-authors of the manuscript**

Please indicate which of the below applies to you:

- We are all US Government employees and the Article is public domain and therefore the 'Assignment of copyright' clause does not apply
- I am a US Government employee but some of my co-authors are not
- I am not a US Government employee but some of my co-authors are
- The work was performed by contractors of the US Government under contract number: .....
- All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted
- Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted

**None of the above**

**The Article is a 'work made for hire' and I am signing as an authorized representative and on behalf of my employer**

Please indicate which of the below applies to you:

- The Article is authored by US Government employees and the Article is public domain and therefore the 'Assignment of copyright' clause does not apply
- The work was performed by contractors of the US Government under contract number: .....
- The Article is authored by UK, Canadian or Australian Government employees and Crown Copyright is asserted

**None of the above**


**Signed on Behalf of Corresponding Author**

Please enter a valid email address.

Please complete this section if you are not the corresponding author as listed above. A copy of the agreement will be sent to you and the corresponding author.

- I am signing on behalf of the corresponding author
- Name, job title and company (if employer representative) .....
- E-mail address.....

Please tick the above boxes (as appropriate), review the Journal Publishing Agreement, and then sign and date the document in black ink.

Signed:  Name printed: Morry Silberstein

Title and Company (if employer representative): \_\_\_\_\_

Date: 19 February 2021

Please return the completed and signed original of this form by mail or fax, or by e-mailing a scanned copy of the signed original, retaining a copy for your files, to:

## THE JOURNAL PUBLISHING AGREEMENT

### Assignment of copyright

I hereby assign to the Copyright Owner the copyright in the manuscript identified above (where Crown Copyright is asserted, authors agree to grant an exclusive publishing and distribution license) and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article"). This assignment of rights means that I have granted to the Copyright Owner the exclusive right to publish and reproduce the Article, or any part of the Article, in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This includes the right to enforce the rights granted hereunder against third parties.

### Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, the Copyright Owner shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials in all forms and media (whether now known or later developed), and to permit others to do so.

### Research Data

"Research Data" shall mean the result of observations or experimentation that validate research findings and that are published separate to the Article, which can include but are not limited to raw data, processed data, software, algorithms, protocols, and methods.

With respect to any Research Data that I wish to make accessible on a site or through a service of the Copyright Owner, the Copyright Owner shall have a perpetual worldwide, non-exclusive right and license to publish, extract, reformat, index, adapt, build upon, redistribute, link to and otherwise use all or any part of the Research Data in all forms and media (whether now known or later developed), and to permit others to do so. Where I have selected a specific end user license under which the Research Data is to be made available on a site or through a service, the publisher shall apply that end user license to the Research Data on that site or service.

### Reversion of rights

Articles may sometimes be accepted for publication but later rejected in the publication process, even in some cases after public posting in "Articles in Press" form, in which case all rights will revert to the author (see: <https://www.elsevier.com/about/our-business/policies/article-withdrawal>).

### Revisions and addenda

I understand that no revisions, additional terms or addenda to this Journal Publishing Agreement can be accepted without the Copyright Owner's express written consent. I understand that this Journal Publishing Agreement supersedes any previous agreements I have entered into with the Copyright Owner in relation to the Article from the date hereof.

### Author Rights for Scholarly Purposes (see 'Definitions' clause below)

I understand that I retain or am hereby granted (without the need to obtain further permission) the Author Rights (see description below and definitions), and that no rights in patents, trademarks or other intellectual property rights are transferred to the Copyright Owner.

The Author Rights include the right to use the Preprint, Accepted Manuscript and the Published Journal Article for Personal Use, Internal Institutional Use. They also include the right to use these different versions of the Article for [Scholarly Sharing](#) purposes, which include sharing:

- the Preprint on any website or repository at any time;
- the Accepted Manuscript on certain websites and usually after an embargo period;
- the Published Journal Article only privately on certain websites, unless otherwise agreed by Copyright Owner.

In the case of the Accepted Manuscript and the Published Journal Article the Author Rights exclude Commercial Use (unless expressly agreed in writing by the Copyright Owner), other than use by the author in a subsequent compilation of the author's works or to extend the Article to book length form or re-use by the author of portions or excerpts in other works (with full acknowledgment of the original publication of the Article).

### Author Representations/Ethics and Disclosure/Sanctions

I affirm the Author Representations noted below, and confirm that I have reviewed and complied with the relevant Instructions to Authors, Ethics in Publishing policy, Declarations of Interest disclosure and information for authors from countries affected by sanctions (Iran, Cuba, Sudan, Burma, Syria, or Crimea). Please note that some journals may require that all co-authors sign and submit Declarations of Interest disclosure forms. I am also aware of the publisher's policies with respect to retractions and withdrawal (<https://www.elsevier.com/about/our-business/policies/article-withdrawal>). For further information see the publishing ethics page at <https://www.elsevier.com/about/our-business/policies/publishing-ethics> and the journal home page. For further information on sanctions, see <https://www.elsevier.com/about/our-business/policies/trade-sanctions>.

### Author Representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.

- Except as expressly set out in this Journal Publishing Agreement, the Article is not subject to any prior rights or licenses and, if my or any of my co-authors' institution has a policy that might restrict my ability to grant the rights required by this Journal Publishing Agreement (taking into account the Author Rights permitted hereunder, including Internal Institutional Use), a written waiver of that policy has been obtained.
- If I and/or any of my co-authors reside in Iran, Cuba, Sudan, Burma, Syria, or Crimea, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See <https://www.elsevier.com/about/our-business/policies/patient-consent> for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this Journal Publishing Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

### Governing Law and Jurisdiction

This Agreement will be governed by and construed in accordance with the laws of the country or state of the Copyright Owner ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see <http://www.elsevier.com/copyright>.

### **DEFINITIONS**

#### **Accepted Manuscript**

The manuscript of an Article that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review, and editor-author communications. The Accepted Manuscript should not be added to or enhanced in any way to appear more like, or to substitute for, the Published Journal Article. The Accepted Manuscript should include a link to the formal publication through the relevant DOI and should bear a Creative Commons CC BY-NC-ND license.

#### **Commercial Use**

The use or posting of Articles:

- for commercial gain – for example by associating advertising with the full-text of the Article, by providing hosting services to other repositories or to other organizations, or charging fees for document delivery or access;
- to substitute for the services provided directly by the publisher – for example article aggregation, systematic distribution via e-mail lists or share buttons, posting, indexing or linking for promotional/marketing activities by commercial companies for use by customers and/or intended target audience of such companies (e.g. pharmaceutical companies and healthcare professionals/physician-prescribers).

#### **Internal Institutional Use**

Use by the author's institution for classroom teaching at the institution and for internal training purposes (including distribution of copies, paper or electronic, and use in coursepacks and courseware programs, but not in MOOCs – Massive Open Online Courses) and inclusion of the Article in applications for grant funding or for patent applications. For authors employed by companies, the use by that company for internal training purposes.

#### **Personal Use**

Use by an author in the author's classroom teaching (including distribution of copies, paper or electronic) or presentation by an author at a meeting or conference (including distribution of copies to the delegates attending such meeting), distribution of copies (including through e-mail) to known research colleagues for their personal use, use in a subsequent compilation of the author's works, inclusion in a thesis or dissertation, preparation of other derivative works such as extending the Article to book-length form, or otherwise using or re-using portions or excerpts in other works (with full acknowledgment of the original publication of the Article).

#### **Preprint**

Author's own write-up of research results and analysis that has not been peer reviewed, nor had any other value added to it by a publisher (such as formatting, copy editing, technical enhancements, and the like). Preprints should not be added to or enhanced in any way in order to appear more like, or to substitute for, the Published Journal Article.

#### **Published Journal Article**

The definitive final record of published research that appears or will appear in the journal and embodies all value-adding publisher activities including peer review co-ordination, copy-editing, formatting, (if relevant) pagination, and online enrichment.

#### **Scholarly Sharing**

**Preprint:** Sharing of Preprints by an author on any website or repository at any time. When the Article is accepted, the author is encouraged to include a link to the formal publication through the relevant DOI. The author can also update the Preprint on arXiv or RePEc with the Accepted Manuscript.

#### **Accepted Manuscript:**

- (i) **immediately on acceptance:** sharing of the Accepted Manuscript by an author:
  - via the author's non-commercial personal homepage or blog

- via the author's research institute or institutional repository for Internal Institutional Use or as part of an invitation-only research collaboration work-group
- directly by providing copies to the author's students or to research collaborators for their personal use
- for private scholarly sharing as part of an invitation-only work group on commercial sites with which the publisher has a hosting agreement

(ii) **after the embargo period:** an author may share the Accepted Manuscript via non-commercial hosting platforms (such as the author's institutional repository) and via commercial sites with which the publisher has a hosting agreement.

To check the embargo period for the journal, go to <http://www.elsevier.com/embargoperiodlist>.

The publisher has agreements with certain funding agencies that may permit shorter embargo periods and/or different sharing guidelines. To learn more about the publisher's policies and agreements with such agencies or institutions go to <http://www.elsevier.com/fundingbodyagreements>.

**Published Journal Article:** the author may share a link to the formal publication through the relevant DOI or may share the Published Journal Article privately with students or colleagues for their personal use, or privately as part of an invitation-only work group on commercial sites with which the publisher has a hosting agreement. Additionally theses and dissertations which contain embedded Published Journal Articles as part of the formal submission may be hosted publicly by the awarding institution with a link to the formal publication through the relevant DOI. Any other sharing of Published Journal Articles is by agreement with the publisher only.

For more information on the publisher's sharing policies please see <https://www.elsevier.com/sharingpolicy>.